To characterize the use of health care services and the corresponding costs of patients with Neurological Disorders (ND) managed at Primary Care Settings (PCS) under usual medical practice. METHODS: A retrospective, multicenter study was carried out. All patients seen by 5 PCS during year 2006 with at least one demand for ND care (CIAP-2: component-7) were included in the analysis. The control group was formed with the rest of patients without NDs. Outcomes measures included sociodemographics, comorbidities, Charlson index (severity), use of health care resources and ambulatory costs (drugs, diagnostic/ therapeutic procedures, referrals and visits). Statistical analysis included descriptive, logistic regression model and ANCOVA models. RESULTS: A total of 80,775 patients were included, of which 19,423 had any ND (24.0%; 95%CI: 23.7 24.3%). Patients requiring health care for their ND were older (46.2 Ϯ 22.1 vs. 38.9 Ϯ 22.9, p < 0.001), with increased severity (0.3 Ϯ 0.6 vs. 0.2 Ϯ 0.5, p < 0.001), predominantly female (63.6 vs. 49.8%, p < 0.001), larger number of health problems (6.1 Ϯ 4.0 vs. 4.3 Ϯ 3.2, p < 0.001) and increased per patient per year medical visits (9.9 Ϯ 9.4 vs. 7.2 Ϯ 7.7, p < 0.001) and days of work absenteeism due to disability (73.3 Ϯ 124.4 vs. 56.8 Ϯ 107.6, p < 0.001). Main symptoms demanding care were: vertigo/dizziness (25.6%) and headache (17.7%). Neurological treatment was associated with women (OR = 1.8), depressive syndrome (OR = 1.5) and cardiovascular events (OR = 1.2), p < 0.0001 in all cases. Crude and adjusted (age, gender and comorbidities) mean annual cost were significantly higher in patients with NDs than in controls; €708. (EDSS). Patients in the model are Ն 21 years of age with RRMS and start in any of the health-states at diagnosis. Patients with an EDSS score below 6.0 receive treatment. Treatment effects for relapse and disease progression were obtained from clinical trials and long-term clinical evidence where available. Transition rates were estimated by applying a percent reduction of treatment effects of therapies to natural history rates of relapse and disease progression. Rates were adjusted for treatment discontinuation and persistent NZ antibodies. Patients incurred drug, other medical and lost worker productivity costs. Patients on NZ incurred additional costs for monitoring, diagnosis, and treatment of progressive multifocal leukoencephalopathy (PML), a possible serious adverse event for patients on NZ. Utility weights for each health-state were taken from published utility assessments for people with RRMS. The primary outcomes of the model were lifetime costs and qualityadjusted life years (QALYs). Costs (2005US$) and outcomes were discounted at 3% annually. RESULTS: The lifetime costs per patient for GA were $352,762 and for NZ were $422,210. QALYs during the lifetime of a patient on GA were 9.303 and 9.300 for a patient on NZ. The incremental cost per QALY for patients on GA and NZ compared to symptomatic treatment alone was $258,464 and $580,119 respectively. GA is costsaving when compared to NZ. PML had very little impact on results. CONCLUSION: While incorporating all the long-term clinical evidence, model results indicated that GA was both less costly and more effective over a patient's lifetime than NZ in treating RRMS.
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Patients requiring health care for their ND were older (46.2 Ϯ 22.1 vs. 38.9 Ϯ 22.9, p < 0.001), with increased severity (0.3 Ϯ 0.6 vs. 0.2 Ϯ 0.5, p < 0.001), predominantly female (63.6 vs. 49.8%, p < 0.001), larger number of health problems (6.1 Ϯ 4.0 vs. 4.3 Ϯ 3.2, p < 0.001) and increased per patient per year medical visits (9.9 Ϯ 9.4 vs. 7.2 Ϯ 7.7, p < 0.001) and days of work absenteeism due to disability (73.3 Ϯ 124.4 vs. 56.8 Ϯ 107.6, p < 0.001). Main symptoms demanding care were: vertigo/dizziness (25.6%) and headache (17.7%). Neurological treatment was associated with women (OR = 1.8), depressive syndrome (OR = 1.5) and cardiovascular events (OR = 1.2), p < 0.0001 in all cases. Crude and adjusted (age, gender and comorbidities) mean annual cost were significantly higher in patients with NDs than in controls; €708.25 Ϯ 900.94 vs. €443.10 Ϯ 678.44, p < 0.001, and €932.87 vs. €712.38, p < 0.001. All per patient per year components of costs (fixed/ semi-fixed, tests, referrals) were significantly higher in the ND group, particularly pharmaceutical expenditure; €621.26 vs. €479.25) p < 0.001. CONCLUSION: Patients requiring care for NDs in the primary care setting showed a large number of comorbidities, increased use of health resources and higher per patient per year cost. (EDSS) . Patients in the model are Ն 21 years of age with RRMS and start in any of the health-states at diagnosis. Patients with an EDSS score below 6.0 receive treatment. Treatment effects for relapse and disease progression were obtained from clinical trials and long-term clinical evidence where available. Transition rates were estimated by applying a percent reduction of treatment effects of therapies to natural history rates of relapse and disease progression. Rates were adjusted for treatment discontinuation and persistent NZ antibodies. Patients incurred drug, other medical and lost worker productivity costs. Patients on NZ incurred additional costs for monitoring, diagnosis, and treatment of progressive multifocal leukoencephalopathy (PML), a possible serious adverse event for patients on NZ. Utility weights for each health-state were taken from published utility assessments for people with RRMS. The primary outcomes of the model were lifetime costs and qualityadjusted life years (QALYs). Costs (2005US$) and outcomes were discounted at 3% annually. RESULTS: The lifetime costs per patient for GA were $352,762 and for NZ were $422,210. QALYs during the lifetime of a patient on GA were 9.303 and 9.300 for a patient on NZ. The incremental cost per QALY for patients on GA and NZ compared to symptomatic treatment alone was $258,464 and $580,119 respectively. GA is costsaving when compared to NZ. PML had very little impact on results. CONCLUSION: While incorporating all the long-term clinical evidence, model results indicated that GA was both less costly and more effective over a patient's lifetime than NZ in treating RRMS.
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